Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind adaptive study of SYS6017 zoster mRNA vaccine in healthy adults aged 40 years and older
CTR20255261Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SYS6017 in herpes zoster (HZ), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Jan 2026; status: active.
02
Drugs
SYS6017
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on CTR20255261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255261.